Cargando…

Impaired expression of protein phosphatase 2A subunits enhances metastatic potential of human prostate cancer cells through activation of AKT pathway

BACKGROUND: Protein phosphatase 2A (PP2A) is a dephosphorylating enzyme, loss of which can contribute to prostate cancer (PCa) pathogenesis. The aim of this study was to analyse the transcriptional and translational expression patterns of individual subunits of the PP2A holoenzyme during PCa progres...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pandey, P, Seshacharyulu, P, Das, S, Rachagani, S, Ponnusamy, M P, Yan, Y, Johansson, S L, Datta, K, Fong Lin, M, Batra, S K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2013
Materias:	Genetics and Genomics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3694226/ https://www.ncbi.nlm.nih.gov/pubmed/23598299 http://dx.doi.org/10.1038/bjc.2013.160

Ejemplares similares

Activated Kras(G12D) is associated with invasion and metastasis of pancreatic cancer cells through inhibition of E-cadherin
por: Rachagani, S, et al.
Publicado: (2011)

Inhibition of hedgehog signaling improves the anti-carcinogenic effects of docetaxel in prostate cancer
por: Mimeault, Murielle, et al.
Publicado: (2015)

FDPS cooperates with PTEN loss to promote prostate cancer progression through modulation of small GTPases/AKT axis
por: Seshacharyulu, Parthasarathy, et al.
Publicado: (2019)

Src homology domain-containing phosphatase 2 suppresses cellular senescence in glioblastoma
por: Sturla, L-M, et al.
Publicado: (2011)

Targeting EGF-receptor(s) - STAT1 axis attenuates tumor growth and metastasis through downregulation of MUC4 mucin in human pancreatic cancer
por: Seshacharyulu, Parthasarathy, et al.
Publicado: (2014)

Evaluation of variation in the phosphoinositide-3-kinase catalytic subunit alpha oncogene and breast cancer risk
por: Stevens, K N, et al.
Publicado: (2011)

MUC16 contributes to the metastasis of pancreatic ductal adenocarcinoma through focal adhesion mediated signaling mechanism
por: Muniyan, Sakthivel, et al.
Publicado: (2016)

An inherited NBN mutation is associated with poor prognosis prostate cancer
por: Cybulski, C, et al.
Publicado: (2013)

Interleukin-1 receptor antagonist haplotype associated with prostate cancer risk
por: Lindmark, F, et al.
Publicado: (2005)

The impact of a BRCA2 mutation on mortality from screen-detected prostate cancer
por: Akbari, M R, et al.
Publicado: (2014)

NFAT signalling is a novel target of oncogenic BRAF in metastatic melanoma
por: Flockhart, R J, et al.
Publicado: (2009)

Mutation analysis of aryl hydrocarbon receptor interacting protein (AIP) gene in colorectal, breast, and prostate cancers
por: Georgitsi, M, et al.
Publicado: (2007)

Genetic and epigenetic changes in primary metastatic and nonmetastatic colorectal cancer
por: Miranda, E, et al.
Publicado: (2006)

PARK2 and proinflammatory/anti-inflammatory cytokine gene interactions contribute to the susceptibility to leprosy: a case–control study of North Indian population
por: Chopra, Rupali, et al.
Publicado: (2014)

Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine
por: Souglakos, J, et al.
Publicado: (2008)

CHEK2 variants associate with hereditary prostate cancer
por: Seppälä, E H, et al.
Publicado: (2003)

Polymorphisms in the CYP1B1 gene are associated with increased risk of prostate cancer
por: Chang, B L, et al.
Publicado: (2003)

Hereditary prostate cancer in African American families: linkage analysis using markers that map to five candidate susceptibility loci
por: Brown, W M, et al.
Publicado: (2004)

Novel HER3/MUC4 oncogenic signaling aggravates the tumorigenic phenotypes of pancreatic cancer cells
por: Lakshmanan, Imayavaramban, et al.
Publicado: (2015)

Polygenic susceptibility to prostate and breast cancer: implications for personalised screening
por: Pashayan, N, et al.
Publicado: (2011)

A personalised approach to prostate cancer screening based on genotyping of risk founder alleles
por: Cybulski, C, et al.
Publicado: (2013)

KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer
por: Birkeland, E, et al.
Publicado: (2012)

Rapid progression of prostate cancer in men with a BRCA2 mutation
por: Narod, S A, et al.
Publicado: (2008)

Focal amplification of the androgen receptor gene in hormone-naive human prostate cancer
por: Merson, S, et al.
Publicado: (2014)

Genetic architecture of prostate cancer in the Ashkenazi Jewish population
por: Vijai, J, et al.
Publicado: (2011)

MUC4 stabilizes HER2 expression and maintains the cancer stem cell population in ovarian cancer cells
por: Ponnusamy, Moorthy P, et al.
Publicado: (2011)

Reduction in O-glycome induces differentially glycosylated CD44 to promote stemness and metastasis in pancreatic cancer
por: Leon, Frank, et al.
Publicado: (2021)

Splice variant PRKC-ζ(-PrC) is a novel biomarker of human prostate cancer
por: Yao, S, et al.
Publicado: (2012)

Mucin (Muc) expression during pancreatic cancer progression in spontaneous mouse model: potential implications for diagnosis and therapy
por: Rachagani, Satyanarayana, et al.
Publicado: (2012)

Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis
por: Edwards, S M, et al.
Publicado: (2010)

Novel role of pancreatic differentiation 2 in facilitating self-renewal and drug resistance of pancreatic cancer stem cells
por: Vaz, A P, et al.
Publicado: (2014)

Mutation analysis of the MSMB gene in familial prostate cancer
por: Kote-Jarai, Z, et al.
Publicado: (2010)

Mutation screening and association study of RNASEL as a prostate cancer susceptibility gene
por: Maier, C, et al.
Publicado: (2005)

ATM polymorphisms as risk factors for prostate cancer development
por: Angèle, S, et al.
Publicado: (2004)

Non-genomic action of resveratrol on androgen and oestrogen receptors in prostate cancer: modulation of the phosphoinositide 3-kinase pathway
por: Benitez, D A, et al.
Publicado: (2007)

Common genetic variation associated with increased susceptibility to prostate cancer does not increase risk of radiotherapy toxicity
por: Ahmed, Mahbubl, et al.
Publicado: (2016)

Circulating leukocyte telomere length and risk of overall and aggressive prostate cancer
por: Julin, B, et al.
Publicado: (2015)

Germline BRCA1 mutations increase prostate cancer risk
por: Leongamornlert, D, et al.
Publicado: (2012)

PD2/Paf1 depletion in pancreatic acinar cells promotes acinar-to-ductal metaplasia
por: Dey, Parama, et al.
Publicado: (2014)

Absence of truncating BRIP1 mutations in chromosome 17q-linked hereditary prostate cancer families
por: Ray, A M, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_e1m8dm6hr7l28r9nqf3e7vk1ca